Female BALB/c mice were immunized with a commercial PCV2 vaccine, and a monoclonal antibody (MAb) designated as 3H11 was achieved by hybridoma techniques. The MAb specifically reacted with Cap protein of PCV2, which has been identified by western blot. Immunoperoxidase monolayer assay results showed that 3H11 did not cross-react with PCV1-infected cells. Therefore, this work suggested that 3H11 could be a useful tool as a specific diagnostic reagent for PCV2 research.
Get full access to this article
View all access options for this article.
References
1.
TischerI, RaschR, and TochtermannG: Characterization of papovavirus-and picornavirus-like particles in permanent pig kidney cell lines. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie, 1974; 226:153–167.
2.
TischerI, MieldsW, WolffD, VagtM, and GriemW: Studies on epidemiology and pathogenicity of porcine circovirus. Arch Virol, 1986; 91:271–276.
3.
GillespieJ, OpriessnigT, MengXJ, PelzerK, and Buechner-MaxwellV: Porcine circovirus type 2 and porcine circovirus-associated disease. J Vet Intern Med, 2009; 23:1151–1163.
4.
PuvanendiranS, StoneS, YuW, JohnsonCR, AbrahanteJ, JimenezLG, GriggsT, HaleyC, WagnerB, and MurtaughMP: Absence of porcine circovirus type 1 (PCV1) and high prevalence of PCV 2 exposure and infection in swine finisher herds. Virus Res, 2011; 157:92–98.
5.
CalsamigliaM, SegalesJ, QuintanaJ, RosellC, and DomingoM: Detection of porcine circovirus types 1 and 2 in serum and tissue samples of pigs with and without postweaning multisystemic wasting syndrome. J Clin Microbiol, 2002; 40:1848–1850.
6.
RenL, ChenX, and OuyangH: Interactions of porcine circovirus 2 with its hosts. Virus Genes, 2016; 52:437–444.
7.
NainysJ, LasickieneR, Petraityte-BurneikieneR, DabrisiusJ, LelesiusR, SereikaV, ZvirblieneA, SasnauskasK, and GedvilaiteA: Generation in yeast of recombinant virus-like particles of porcine circovirus type 2 capsid protein and their use for a serologic assay and development of monoclonal antibodies. BMC Biotechnol, 2014; 14:100.
8.
YeY, ChengX, ZhangJ, TongT, LinW, LiaoM, and FanH: Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2. Virol J, 2013; 10:316.
9.
NawagitgulP, HarmsPA, MorozovI, ThackerBJ, SordenSD, LekcharoensukC, and PaulPS: Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV. Clin Diagn Lab Immunol, 2002; 9:33–40.
10.
DulacGC, and AfsharA: Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs. Can J Vet Res, 1989; 53:431–433.
11.
ShangSB, JinYL, JiangXT, ZhouJY, ZhangX, XingG, HeJL, and YanY: Fine mapping of antigenic epitopes on capsid proteins of porcine circovirus, and antigenic phenotype of porcine circovirus type 2. Mol Immunol, 2009; 46:327–334.
12.
XiX, MoX, XiaoY, YinB, LvC, WangY, SunZ, YangQ, YaoY, XuanY, LiX, YuanYA, and TianK: Production of Escherichia coli-based virus-like particle vaccine against porcine circovirus type 2 challenge in piglets: Structure characterization and protective efficacy validation. J Biotechnol, 2016; 223:8–12.
13.
WangG, WangY, LiCY, GaoTW, and LiuYF: Thiocyanate elution measurement of relative affinity of phage antibodies. Sheng Wu Gong Cheng Xue Bao, 2004; 20:429–433.
14.
HardingJC: The clinical expression and emergence of porcine circovirus 2. Vet Microbiol, 2004; 98:131–135.
15.
ShenHG, HalburPG, and OpriessnigT: Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA. J Gen Virol, 2012; 93:1345–1355.
